MapLight Therapeutics, Inc. Common Stock - Asset Resilience Ratio
MapLight Therapeutics, Inc. Common Stock (MPLT) has an Asset Resilience Ratio of 53.88% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of MapLight Therapeutics, Inc. Common Stock to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2025)
This chart shows how MapLight Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. See MapLight Therapeutics, Inc. Common Stock balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down MapLight Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MapLight Therapeutics, Inc. Common Stock stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $258.37 Million | 53.88% |
| Total Liquid Assets | $258.37 Million | 53.88% |
Asset Resilience Insights
- Very High Liquidity: MapLight Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 53.88% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
MapLight Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare MapLight Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for MapLight Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual Asset Resilience Ratio data for MapLight Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 53.88% | $258.37 Million | $479.51 Million | +2.36pp |
| 2024-12-31 | 51.52% | $70.54 Million | $136.92 Million | -- |
About MapLight Therapeutics, Inc. Common Stock
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irrit… Read more